Drug Trial Radar · NCT06502743
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Sep 12, 2024
Primary completion
Dec 27, 2027
Study completion Dec 27, 2027
Sponsor
- Lead sponsor
- Yonsei UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Onconic Therapeutics Inc.; Merck Sharp & Dohme LLC
- First posted
- Jul 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is listed below. Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%. Part B (Randomization Phase) : To evaluate the efficacy of pembrolizumab and nesuparib combination/ pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator assessed progression free survival (PFS) as assessed by RECIST 1.1.
Conditions
- Endometrial Cancer
- Recurrent Endometrial Carcinoma
- Endometrial Carcinoma
- Gynecologycal Cancer
- Endometrial Neoplasms
Interventions
NesuparibDrug
Nesuparib 150mg or 100mg, QD, PO
PembrolizumabDrug
Pembrolizumab 400mg, IV, Q6W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicitiesTime frame: Assessed during 21days from day 1 of first combination maintenance treatment cycle (i.e., 21 days of Cycle 8 from day 1)
- Overall distribution of progression-free survivalTime frame: Approximately 11.01 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Severance hospital
Seoul, South Korea · Recruiting
Korea University Guro Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul Asan Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
National Cancer Center
Goyang-si, Kyeonggi-do, South Korea · Recruiting
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.